Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, comments on the addition of anti-CD38 monoclonal antibodies to lenalidomide as a post-autologous stem cell transplantation (autoSCT) maintenance strategy in newly diagnosed multiple myeloma (NDMM), highlighting clinical trials evaluating this strategy. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.